Rabeprazole Hydroxy Compound CAS 675198-19-3 Purity > 99.5% (HPLC) Factaraidh
Solarachadh Ceimigeach Ruifu Rabeprazole Sòidiam Eadar-mheadhanach
Sòidiam Rabeprazole CAS 117976-90-6
Compound Hydroxy Rabeprazole CAS 675198-19-3
Compound cloride Rabeprazole CAS 153259-31-5
Ainm Ceimigeach | [4- (3-Methyoxypropoxy)-3-Methyl-2-Pyridinyl]methanol Hydrochloride |
Co-fhaclan | Compound Hydroxy Rabeprazole;(4- (3-Methoxypropoxy) -3-Methylpyridin-2-yl)methanol Hydrochloride;4- (3-Methoxypropoxy)-3-Methylpyridine-2-Methanol Hydrochloride |
Àireamh CAS | 675198-19-3 |
Àireamh CAT | RF-PI1919 |
Inbhe Stoc | Ann an stoc, ìre toraidh suas gu tonna |
Foirmle Molecular | C11H18ClNO3 |
Cuideam Molecular | 247.72 |
Brand | Ceimigeach Ruifu |
Nì | Sònrachaidhean |
Coltas | Pùdar criostalach aotrom buidhe |
Modh Assay / Mion-sgrùdadh | > 99.5% (HPLC) |
Call air tiormachadh | <0.50% |
Fuigheall air Ignition | <0.20% |
Singilte Impurity sam bith | <0.50% |
Neo-dhìomhaireachd iomlan | <0.50% |
Meatailtean Trom | <20ppm |
Inbhe deuchainn | Inbhe Iomairt |
Cleachdadh | Eadar-mheadhanach de Rebeprazole Sòidiam (CAS: 117976-90-6) |
Rabeprazole Hydroxy Compound CAS 675198-19-3 Slighe Synthetic
Pacaid: Botal, poca foil alùmanum, 25kg / druma cairt-bhòrd, no a rèir riatanas luchd-ceannach
Suidheachadh stòraidh:Bùth ann an soithichean dùinte ann an àite fionnar is tioram;Dìon bho sholas is taiseachd
Tha [4-(3-Methyoxypropoxy)-3-Methyl-2-Pyridinyl]methanol Hydrochloride, Rabeprazole Hydroxy Compound, (CAS: 675198-19-3) na eadar-mheadhanach de Rebeprazole Sòidiam (CAS: 117976-90-6).Is e clas inhibitor pumpa proton a th ’ann an canker sodium azole Rabeprazole a’ gabhail na drogaichean, airson cruth salann sodium ray Bella azole, an toiseach leis a ’chompanaidh Iapanach Eisai air a leasachadh gu soirbheachail airson a’ chiad uair, ainm bathar airson feachd tonn, is e àite luchd-dìon pumpa proton lùghdachadh gastric acid secretion de stàball tinneas raointean, gus a leigheas an stamag agus duodenal ulcers agus stamag esophagus regurgitation bhuaidh galar.Tha e air a chleachdadh sa mhòr-chuid ann an làimhseachadh clionaigeach de ghalaran co-cheangailte ri searbhag, leithid taghadh ulcer gastric agus duodenal, ulcer peptic, galar reflux gastroesophageal, syndrome zhuoye agus mar sin air adhart.Tha tòiseachadh gnìomh nas luaithe aig sodium Rebeprazole an coimeas ri omeprazole, ach ùine gnìomh nas giorra.Tha Rabeprazole na ionad benzimidazole a chuireas casg air secretion searbhag gastric le bhith a’ ceangal ri pumpa proton de cheallan parietal gastric.Tha an toradh seo a’ cur bacadh air gnìomh adenosine triphosphate, prìomh enzyme ann a bhith a’ dèanamh searbhag gastric.Faodaidh e casg a chuir air secretion searbhag gastric bunaiteach agus searbhag gastric air adhbhrachadh le brosnachadh.